Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules01:18

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

339
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
339
Physical Assessment of the Respiratory Tract II: Inspection01:27

Physical Assessment of the Respiratory Tract II: Inspection

945
Physical assessment of the respiratory tract through inspection is a crucial step in understanding the patient's respiratory health. It provides insights into the functioning of the respiratory system, the musculoskeletal structure, and even the patient's nutritional status. This comprehensive approach involves observing several vital aspects: chest configuration, breathing patterns, respiratory rates, skin color, and use of accessory muscles.
Chest Configuration
The chest configuration...
945
Physical Assessment of the Respiratory Tract II: Palpation01:24

Physical Assessment of the Respiratory Tract II: Palpation

2.0K
Physical assessment of the respiratory tract is critical in identifying potential health issues. One key component of this assessment is palpation, a technique healthcare providers use to assess the body for abnormalities. This content explores the method of palpation in evaluating the respiratory tract, focusing on thoracic palpation and tactile fremitus.
Thoracic Palpation
Thoracic palpation detects tenderness, masses, lesions, respiratory excursions, and vocal fremitus. The nurse assesses...
2.0K
Assessment of the Gastrointestinal System I: Subjective Data01:17

Assessment of the Gastrointestinal System I: Subjective Data

690
Assessing the gastrointestinal (GI) system is a complex process that begins with collecting subjective data. This data, collected through patient interviews, provides crucial insights into the patient's health history, perception patterns, and lifestyle habits, all contributing significantly to GI health.
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems...
690
Assessment of the Cardiovascular System I: Subjective Data01:23

Assessment of the Cardiovascular System I: Subjective Data

927
A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
927
Physical Assessment of the Respiratory Tract I: Health History01:28

Physical Assessment of the Respiratory Tract I: Health History

937
Physical assessment of the respiratory tract is critical to patient care. It allows healthcare professionals to identify and manage various respiratory conditions. The process involves a combination of subjective and objective data collection.
Subjective Data
Subjective data provides vital information about the patient's health history and symptoms. This data is typically collected through interviews in which patients describe their experiences, symptoms, and concerns.
Health history and...
937

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

From candidate ranking to lead identification - Hydrophobic interaction chromatography, PAIA, and structure-based calculations for hydrophobicity determination during developability assessment of mAbs and a mAb-derived fusion protein.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V·2026
Same author

Lyophilization of a viral vaccine: Strategies for surrogate use in analytical characterization of cake properties and considerations on virus infectivity.

Journal of pharmaceutical sciences·2026
Same author

Optimizing LOD/LOQ and sample consumption during analytical ultracentrifugation to characterize AAV gene therapy vectors.

Journal of pharmaceutical and biomedical analysis·2026
Same author

Single Ni Atoms Drive Carboxyl Deprotonation in Metal-Organic Chains.

ACS nano·2026
Same author

Drug Product Development of Lipid Nanoparticle-Based mRNA Therapeutics and Vaccines.

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology·2026
Same author

Evaluation of dimethyl sulfoxide-free formulations for cryopreservation of human T cells.

Journal of pharmaceutical sciences·2026

関連する実験動画

Updated: Feb 12, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.3K

タンパク質製剤の開発可能性評価のためのデータ駆動型および物理ベースモデルを組み合わせた新しいインシリコプラットフォーム

Andrea Arsiccio1, Kristian Le Vay1, Andre Sao Pedro1

  • 1Coriolis Pharma Research GmbH, Fraunhoferstr. 18 b, 82152 Martinsried, Germany.

Journal of pharmaceutical sciences
|February 10, 2026
PubMed
まとめ

この研究は、タンパク質配列のみを使用して治療用タンパク質の安定性と製剤ニーズを予測する新しい計算プラットフォームを紹介する。このアプローチは、早期のリスク評価を可能にすることで、コストのかかる薬剤開発の失敗を減らす。

キーワード:
バイオ医薬品特性評価インシリコモデリング機械学習分子動力学タンパク質タンパク質製剤

さらに関連する動画

Erythrocyte Sedimentation Rate: A Physics-Driven Characterization in a Medical Context
08:07

Erythrocyte Sedimentation Rate: A Physics-Driven Characterization in a Medical Context

Published on: March 24, 2023

4.0K
Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform
09:41

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform

Published on: February 25, 2021

25.4K

関連する実験動画

Last Updated: Feb 12, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.3K
Erythrocyte Sedimentation Rate: A Physics-Driven Characterization in a Medical Context
08:07

Erythrocyte Sedimentation Rate: A Physics-Driven Characterization in a Medical Context

Published on: March 24, 2023

4.0K
Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform
09:41

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform

Published on: February 25, 2021

25.4K

科学分野:

  • バイオ医薬品開発
  • 計算化学
  • タンパク質工学

背景:

  • 治療用タンパク質の開発には多額の投資が必要であり、高い失敗率に直面しています。
  • 失敗は、特に開発初期段階における分子不安定性と製剤上の課題に起因することがよくあります。
  • 開発初期段階での薬物物質の不足は、計算モデリングのような代替評価方法を必要とします。

研究 の 目的:

  • 治療用タンパク質製剤開発可能性評価のための新しいインシリコプラットフォームを発表する。
  • コストのかかる薬剤開発の失敗に関連する時間的および金銭的リスクを削減する。
  • 物理的な材料を必要とせず、タンパク質の一次配列のみを必要とする方法を提供する。

主な方法:

  • データ駆動型および物理ベースモデルを統合した新しいインシリコプラットフォームの開発。
  • 構造予測、バイオインフォマティクス、機械学習、分子動力学を含む計算技術を利用。
  • プラットフォームの入力は、治療用タンパク質の一次アミノ酸配列です。

主要な成果:

  • プラットフォームは、タンパク質の潜在的な問題点と外れ値的な特性を特定します。
  • 高濃度製剤への適合性を評価し、自己相互作用に対する製剤条件の影響をスクリーニングします。
  • 治療用タンパク質の最適な製剤化の範囲を提案します。

結論:

  • 開発されたインシリコプラットフォームは、タンパク質医薬品候補の初期段階評価のための強力なツールを提供します。
  • 物理的な材料なしで製剤開発可能性を予測することにより、リスクを低減します。
  • ケーススタディは、実世界のシナリオにおけるプラットフォームの適用性と実験的検証を示しています。